Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 4/20 | 0.43 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 3/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.42 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.42 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.42 |
| ▸ | SOD1 | P00441 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2726596 | 0.88 | CA12 (0.42) | — | |
| SCHEMBL6012035 | 0.86 | PTGS2 (0.41) | DRD4DRD2DRD3MAOBPTGS2 | |
| SCHEMBL10944086 | 0.83 | FFAR1 (0.41) | DRD4DRD2DRD3MAOBPTGS2 | |
| SCHEMBL16519364 | 0.81 | MMP2 (0.39) | — | |
| SCHEMBL8341250 | 0.80 | DRD4 (0.41) | DRD4DRD2DRD3MAOBGPR84 | |
| SCHEMBL5536818 | 0.78 | DRD4 (0.49) | DRD4DRD2DRD3MAOBGPR84 | |
| SCHEMBL12966373 | 0.78 | HPGD (0.41) | APP | |
| Formic Acid SCHEMBL15743072 | 0.78 | HPGD (0.50) | MAOBPTGS2MAOA | |
| SCHEMBL24933380 | 0.77 | APP (0.50) | APP | |
| SCHEMBL17845804 | 0.77 | APP (0.47) | DRD4DRD2DRD3MAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 189 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2616077-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) | 2013-07-24 | — | — | EP | claimed |
| WO-2012035423-A1 | ANTI-CANCER ACTIVITY OF NOVEL BICYCLIC HETEROCYCLES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-03-22 | — | — | WO | claimed |
| EP-3704094-B1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | DOMAIN THERAPEUTICS (FR) | 2026-01-20 | — | — | US | disclosed |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC (US) | 2025-04-17 | — | — | US | disclosed |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ABBVIE INC. | 2024-05-23 | — | — | US | disclosed |
| EP-4356971-A2 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2024-04-24 | — | — | EP | disclosed |
| EP-4038052-B1 | PROSTAGLANDIN E2 (PGE2) EP4 RECEPTOR ANTAGONISTS | DOMAIN THERAPEUTICS (FR) | 2024-02-07 | — | — | EP | disclosed |
| WO-2023250107-A1 | PROCESS FOR PREPARING MODULATORS OF EUKARYOTIC INITIATION FACTOR 2B | DENALI THERAPEUTICS INC. (US) | 2023-12-28 | — | — | WO | disclosed |
| EP-2968347-B1 | MODULATORS OF THE EIF2ALPHA PATHWAY | UNIV CALIFORNIA (US) | 2023-08-02 | — | — | EP | disclosed |
| EP-3481383-B1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRRITABLE BOWEL SYNDROME | CELLIX BIO PRIVATE LTD (IN) | 2023-06-14 | — | — | EP | disclosed |
| US-4647579-A | Circulation active novel substituted 4-hydroxy-benzopyrans | BAYER AKTIENGESELLSCHAFT (DE) | 1987-03-03 | — | — | US | disclosed |
| US-4563458-A | CIRCULATORY SYSTEM DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 1986-01-07 | — | — | US | disclosed |
| EP-0158164-A2 | Substituted 4-hydroxy-benzopyrans, process for their preparation and their use in medicines | BAYER AG (DE) | 1985-10-16 | — | — | EP | disclosed |
| US-4474999-A | Phenol compounds, process and polymers | GENERAL ELECTRIC COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0114374-A1 | Substituted 4-aminomethylene chromans or chromenes, process for their preparation and their use in medicines | BAYER AG (DE) | 1984-08-01 | — | — | EP | disclosed |
| US-4415724-A | Branched aromatic polycarbonate from tetraphenol | GENERAL ELECTRIC COMPANY (US) | 1983-11-15 | — | — | US | disclosed |
| US-4090861-A | Herbicidal 1,3-oxathiolan-5-ones | SHELL OIL COMPANY (US) | 1978-05-23 | — | — | US | disclosed |
| US-4062670-A | 4-OXAZOLIDONES OR THIAZOLIDONES | SHELL OIL COMPANY (US) | 1977-12-13 | — | — | US | disclosed |
| US-4019892-A | 2-PHENOXYMETHYL-1,3-OXAZOLIDIN-4-ONE DERIVATIVES | SHELL OIL COMPANY (US) | 1977-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527779-B2 | Prostaglandin E2 (PGE2) EP4 receptor antagonists | PTGER1, PTGER4, PTGER3 | DRD4 617/4885DRD2 587/4885DRD3 393/4885 |
| US-20250122188-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DRD4 3678/4885DRD2 3271/4885DRD3 3495/4885 |
| US-20240166652-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, DDIT3 | DRD4 3678/4885DRD2 3271/4885DRD3 3495/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.